About US
Contact us
-
Sanofi-Aventis to Complete Overdue Genzyme AcquisitionFrench pharmaceutical firm Sanofi-Aventis has reached an agreement to acquire US-based biotechnology firm Genzyme for $20.1bn. Sanofi-Aventis had initially made a formal offer for Genzyme in Augus2011/2/17
-
UK Takes U-Turn on Chinese Medicine BanThe UK Government will allow several unlicensed herbal and Chinese medicines to escape a proposed European ban, which was due to go ahead in April. The controversial move will see health food shops2011/2/17
-
Lilly's Mirror Portfolio Reaches MilestoneLilly's Mirror Portfolio, a concept created to access exterior innovation, has acquired two molecules through an independent venture capitalist firm participating in the programme. One molecule, d2011/2/17
-
Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotideSanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Sunnybrook Health Sciences Centre (Toronto, Canada) announced that they have entered into a research agreement and licensing option for vasculotide, an2011/2/17
-
FDA Funding to RiseThe US Food and Drug Administration (FDA) budget is set to rise by $147m to $2.7bn under President Obama's 2012 budget proposal. The agency is also set to receive approximately $1.6bn in fees paid2011/2/16
-
Study shows lower success rate of FDA drug approval from 2003 to 2010Biotechnology Industry Organization (BIO) Industry Analysis and BioMedTracker (BMT) announced results of a study today that shows the overall success rate for drugs moving through clinical trials to F2011/2/16
-
Sanofi-Aventis Seeks1 Billion Euro Eye-Care AcquisitionsFrench drug maker Sanofi-Aventis (EPA:SAN) is exploring the possibility to make four acquisitions in the ophthalmology sector for EUR1bn (USD1.35bn) in total, French daily Les Echos reported today, ci2011/2/15
-
Cancer Drug Used in Combination with Other Therapies Associated With Increased Risk of DeathCHICAGO, Feb. 1, 2011—An analysis of previous studies indicates that compared with chemotherapy alone, use of the cancer drug bevacizumab in combination with chemotherapy or biological therapy is asso2011/2/15
-
Three Day Excipient GMP Auditing Workshop- Arlington VATuesday April 5-Thursday April 7, 2011 Three day Workshop Content A comprehensive workshop in excipient auditing for makers and users. Training will analyze the essential elements of excipient g2011/2/15
-
Another Recall for McNeilJ&J sales affected by recalls, plant shutdown The new year brought news of yet another recall for McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson (J&J) of New Brunswick, N.J2011/2/12